6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 14 June,2004 By /s/Ronald Lea Erratt Company Secretary

ASX MEDIA RELEASE
14 JUNE 2004

MARSHALL EDWARDS, INC., NAMES SECOND STUDY SITE IN MULTI-NATIONAL
OVARIAN CANCER TRIAL OF INVESTIGATIONAL ANTI-CANCER DRUG PHENOXODIOL

(Washington, DC June 14, 2004). The Royal Women's Hospital
in Melbourne, Australia, today became the second site to enrol
cancer patients in a study of the ability of phenoxodiol, to
restore the sensitivity of ovarian cancer cells to the
standard chemotherapies, paclitaxel and cisplatin. The trial
is also being conducted at Yale-New Haven Hospital, Connecticut.

Researchers are evaluating phenoxodiol for its ability
to enhance the anti-cancer effect of standard chemotherapies,
as well as restore sensitivity in cancers that have become
refractory to standard chemotherapies. In the laboratory,
phenoxodiol has been found to boost dramatically the ability
of low doses of chemotherapy to treat ovarian cancer.

This trial follows a successful Phase I/II study
conducted at Yale-New Haven Hospital that looked at
phenoxodiol as a monotherapy in late-stage ovarian
cancer patients. Researchers from Yale reported at
the American Association of Cancer Research conference
in April 2004, that subsequent to that trial, four of
five patients classified as being refractory to paclitaxel
showed a substantial response as determined by Rustin
criteria on re-challenge with paclitaxel following a
course of phenoxodiol therapy.

Patients in this study will have late-stage ovarian
cancer that has become refractory to the standard
first-line chemotherapies - paclitaxel and cisplatin.
A refractory cancer is one that continues to grow
despite chemotherapy. Women on the trial will be
randomised to one of three treatment arms
(1) paclitaxel only, (2) paclitaxel plus phenoxodiol,
and (3) cisplatin plus phenoxodiol. The paclitaxel-only
treatment arm has been included to confirm the refractory
status of the cancers, which is a requirement for
regulatory approval of drug registration. Women in the
paclitaxel-only arm will be offered phenoxodiol
plus paclitaxel combination treatment once their
refractory status is confirmed.

The development of chemo-resistance in cancers has
been associated with the over-production within cancer
cells of the anti-apoptotic protein, XIAP. Phenoxodiol
has been found in the laboratory to restore chemo-sensitivity
by removal of XIAP, an effect that is restricted to
cancer cells.

Michael Quinn, M.D., who is leading the study at the Royal
Women's Hospital, said, "This is an opportunity that
we hope will provide a benefit for women who have become
unresponsive to chemotherapy. Currently we can offer
nothing in the way of therapy for these patients, but
the promising clinical response that the Yale University
Medical School doctors obtained with phenoxodiol in
refractory patients gives us cause to hope that that
will change."

Phenoxodiol is an investigational drug and, as such, is
not marketed in the United States.

Phenoxodiol is developed by pharmaceutical company
Marshall Edwards, Inc. (LSE AIM: MSH - Nasdaq: MSHL),
which manages its international research and development
programs using the expertise and clinical research
capabilities of universities and hospitals in the U.S.,
Australia and Europe.

Marshall Edwards, Inc., has licensed rights to
bring phenoxodiol to market globally from its parent
company, Novogen Limited. (ASX: Novogen - Nasdaq: NVGN).
Novogen is developing a range of therapeutics across the
fields of oncology, cardiovascular disease and
inflammatory diseases based on its phenolic drug
technology platform.


More information on the Novogen group of companies
and their associated technology developments can be
found at www.novogen.com and at www.marshalledwardsinc.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088